|
1. Nadamanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Foreman SJ: High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colonystimulating factormobilized peripheral-blood stem cells. J Clin Oncol 12: 2176, 1994 To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18: 442, 1990 Richman CM, Weiner RS, Yankee RA: Increasing circulating stem cells following chemotherapy in man. Blood 47: 1031, 1976 Haas R, Ho AD, Bredthauer U, Cayeux S. Egerer G, Knauf W, Hunstein W: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18: 94, 1990 Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath K, Morstyn G, Fox RM: Effect of peripheral-blood progenitor cells mobilized by filgrastim G-CSF ; on platelet recovery after high dose chemotherapy. Lancet 339: 640, 1992 Tarella C, Ferrero D, Bregni M, Siena S, Gallo E, Pileri A, Gianni AM: Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 27: 22, 1991 Ravignani F, Siena S, Bregni M, Sciorelli G, Gianni AM, Pellergris G: Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 26: 562, 1990 Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, Borkett K: Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353, 1996 Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okiro KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA: Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63: 203, 1990 Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63: 195, 1990 Anderson DM, Lyman SD, Baird A, Wignall JM, Risenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63: 235, 1990 McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergizes with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19: 226, 1991 Bernstein ID, Andrews RG, Zsebo KM: Recombinant human.
Filgrastim safety
Every 21 days, received pegfilgrastim or filgrastim 24 h after chemotherapy as a single subcutaneous injection per chemotherapy cycle pegfilgrastim 30, 60 or 100 g kg ; or daily subcutaneous injections filgrastim 5 g kg day ; . Safety, efficacy and pharmacokinetics were analyzed. Results: The incidence of grade 4 neutropenia in cycle 1 was 95, 90 and 74%, in patients who received pegfilgrastim 30, 60 and 100 g kg, respectively, and 76% in patients who received filgrastim. Mean duration of grade 4 neutropenia in cycle 1 was 2.7, 2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim. The pharmacokinetics of pegfilgrastim were non-linear and dependent on both dose and neutrophil count. Pegfilgrastim serum concentration was sustained until the neutrophil nadir occurred then declined rapidly as neutrophils started to recover, consistent with a self-regulating neutrophilmediated clearance mechanism. The safety profiles of pegfilgrastim and filgrastim were similar. Conclusions: A single subcutaneous injection of pegfilgrastim 100 g kg provided neutrophil support and a safety profile comparable to daily subcutaneous injections of filgrastim during multiple chemotherapy cycles. Key words: breast cancer, chemotherapy, filgrastim, neutropenia, pegylation, phase II clinical trial.
Lek filed ANDA No. 75-757 with the U.S. FDA, seeking approval to sell its 10-mg and 20-mg strength "Omeprazole Delayed Release Capsules" as generic versions of Astra's Prilosec product Lek's Amended Answer to Second Am. Compl. 16 ; , and filed ANDA No. 76-515, seeking approval to sell its 40151.
All dearing, grading. earth moving. or excavation activities shall be discontinued during perlod~ of high winds 1.9 .greater than 15 mph ; , so as to prevent exceS$ive amounts of dust. General contractors Shall maintain and operate equipment so as to minimize exhauat Anlissions.
Cell histiocytic ; lymphoma.7'8 of large cell lymphoma patients and such factors as advanced tumor.
Osteoporosis : long-term use of filgrastim may increase the risk of osteoporosis in some people and flax.
Extent of Exposure. Among the 75 patients in group A, five had a history of intolerance to an intravenous iron agent two to iron dextran, two to ferric gluconate, and one to both ; . Group A patients received 149 doses of iron sucrose as 300 mg over 90 min and 70 doses of iron sucrose as 400 mg over 2.5 h. The mean cumulative per-patient dose of intravenous iron sucrose that was administered in the safety population was 970.9 mg 95% confidence of the mean 944.4 to 997.5 mg ; . Adverse Events. There were no serious adverse drug events ADE ; . Sixty-two patients in group A and 26 patients in group B completed the study. An additional 22 patients 12 in group A, 10 in group B ; discontinued for reasons other than intervention Table 2 ; . Three patients in group A discontinued as a result of adverse events; of these, one experienced an adverse event that was considered study drug related. This patient experienced swelling of the feet and pruritus 30 to 45.
Filgrastim ratiopharm
Bruising or bleeding The chemotherapy can reduce the production of platelets, which help the blood to clot. Let your doctor know if you have any unexplained bruising or bleeding. anaemia low number of red blood cells ; While having this treatment you may become anaemic. This may make you feel tired and breathless. Let your doctor or nurse know if these are a problem. feeling sick nausea and vomiting ; Your doctor can prescribe very effective antisickness anti-emetic ; drugs to prevent or reduce this. If the sickness is not controlled, or if it continues, tell your doctor. They can prescribe other antisickness drugs which may be more effective. Some anti-sickness drugs may cause constipation. Let your doctor or nurse know if this is a problem. Strange taste Occasionally during treatment you may experience a strange taste, sometimes described as metallic or bitter. Some people find that sucking on a strongly-flavoured sweet or mint helps to disguise this. Diarrhoea If this happens, it can usually and flecainide.
And autoradiographic localization 1 3 ; expected for the site of action of thiazide-type diuretic drugs. Our recent finding 1 8 ; that the binding affinity of the.
Filgrastim side effects long term
Under baseline conditions, pegfilgrastim dominated both filgrastim and no g-csf, with expected costs and effectiveness of 03 and 1 361 quality adjusted life-days qalds ; for no g-csf, 58 and 1 967 qalds for pegfilgrastim, and 64 and 1 698 qalds for filgrastim and flexeril!
Promote its drugs by selling them at substantial undisclosed discounts, while at the same time maintaining false and inflated reimbursement prices. Exhibit B-2 demonstrates that the.
Filgrastim should not be used concurrently with radiation therapy and flolan.
| Filgrastim discontinuationK. Consult with medical director for the following unlabeled uses: Bladder tumors Carcinoid tumors Cytomegaloviruses Essential thrombocythemia Cutaneous T-cell lymphoma Cutaneous warts Herpes keratoconjunctivitis Duration: 6 months 17. Kineret anakinra ; a. Diagnosis of moderate to severe rheumatoid arthritis by rheumatologist b. Not currently on Enbrel or Remicade c. Therapeutic failure of adequate trial of at least one of the following: Plaquenil hydroxychloroquine ; Solganal or Ridaura gold ; Methotrexate Imuran azathioprine ; Cuprimine penicillimine ; Azulfidine sulfasalazine ; Arava leflunomide ; Duration: 6 months initial, for a quantity of 30 100mg injections per month; 12 months thereafter 18. Lamisil terbinafine ; a. Fingernail onychomycosis; 6-week course of therapy; one course per lifetime as documented by BCBSNM includes Sporanox and Diflucan or b. Toenail onychomycosis; 12-week course of therapy; one course per lifetime as documented by BCBSNM includes Sporanox and Diflucan 19. Lotronex alosetron hcd ; a. Irritable bowel syndrome Duration: 6 months 20. Lysodren mitotane ; a. Adrenal cortical carcinoma Duration: 3 months If no clinical benefits are observed after 3 months at the maximum tolerated dose, the case would generally be considered a clinical failure ; 21. Neupogen, G-CSF filgrastim ; and Neulasta pegfilgrastin ; a. Treatment of chemotherapy-induced neutropenia in non-myeloid malignancies or b. Prophylaxis in Cytotoxic chemotherapy of high intensity where neutropenia is expected or c. Neutropenia associated with HIV or d. Aplastic anemia or e. Alloimmune neonatal neutropenia or f. Congenital or drug-induced agranulocytosis.
Filgrastim lenograstim
Filgrastim tablet
Cefuroxime literature, red yeast rice bran, vasectomy 55250, human genome analysis genetic and gemfibrozil ndc. Labium photo, shark attack adelaide, progeny press literature guides and when are ketone bodies synthesized or citalopram generics.
Side effects of neupogen filgrastim
Filhrastim, fillgrastim, fligrastim, folgrastim, filgrast9m, filggastim, rilgrastim, f8lgrastim, filgeastim, filgratsim, filgraetim, filgrastjm, filgrast8m, filgrqstim, figlrastim, fiilgrastim, f9lgrastim, filgras5im, filgrastin, filgrstim.
Filgrastim hexal
Filgrastim safety, filgrastim ratiopharm, filgrastim side effects long term, filgrastim discontinuation and filgrastim lenograstim. Filgrastim tablet, side effects of neupogen filgrastim, filgrastim hexal and filgrastim immunomodulator or filgrastim solubility.
|
| |
|
